BIND Therapeutics, Inc. (BIND) - NASDAQ
From other sites
Company Description
BIND Therapeutics, Inc. is a clinical stage nanomedicine platform company. The company develops Accurins, which are selective and programmable therapeutics. It main drug candidates are BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant... More
Sector: Healthcare
Industry: Biotechnology
Country: United States